European consensus-based interdisciplinary guideline for invasive cutaneous squamous cell carcinoma: Part 2. Treatment-Update 2023

被引:31
作者
Stratigos, Alexander J. [1 ,2 ]
Garbe, Claus [1 ,2 ]
Dessinioti, Clio [1 ,3 ]
Lebbe, Celeste [3 ,4 ,5 ,6 ]
van Akkooi, Alexander [4 ,5 ,6 ,7 ]
Bataille, Veronique [7 ,8 ]
Bastholt, Lars [8 ,10 ]
Dreno, Brigitte [9 ,11 ]
Dummer, Reinhard [10 ,12 ]
Fargnoli, Maria Concetta [11 ,13 ]
Forsea, Ana Maria [12 ,14 ]
Harwood, Catherine A. [13 ,15 ]
Hauschild, Axel [14 ,16 ]
Hoeller, Christoph [15 ,17 ]
Kandolf-Sekulovic, Lidija [16 ,18 ]
Kaufmann, Roland [17 ,19 ,20 ]
Kelleners-Smeets, Nicole W. J. [18 ,19 ,21 ]
Lallas, Aimilios [2 ,20 ]
Leiter, Ulrike [2 ,22 ]
Malvehy, Josep [21 ,23 ]
del Marmol, Veronique [22 ,24 ]
Moreno-Ramirez, David [23 ,25 ]
Pellacani, Giovanni [24 ,26 ,27 ]
Peris, Ketty [25 ,26 ,28 ]
Saiag, Philippe [27 ,28 ,29 ]
Tagliaferri, Luca [29 ,30 ]
Trakatelli, Myrto [30 ]
Ioannides, Dimitrios [20 ,31 ]
Vieira, Ricardo [31 ,32 ]
Zalaudek, Iris [32 ,33 ]
Arenberger, Petr [33 ,34 ,38 ]
Eggermont, Alexander M. M. [34 ,35 ,36 ,37 ]
Roecken, Martin [2 ,35 ]
Grob, Jean-Jacques [36 ,37 ,38 ]
EADO [9 ,39 ,40 ]
EDF
ESTRO
UEMS
EADV
EORTC
机构
[1] Natl & Kapodistrian Univ Athens, Andreas Sygros Hosp, Dept Dermatol Venereol 1, Athens, Greece
[2] Eberhard Karls Univ Tubingen, Ctr Dermatooncol, Dept Dermatol, Tubingen, Germany
[3] Nord Univ Paris Cite, Univ Paris Cite, Hop St Louis, AP HP,Canc Inst,Dermatooncol, Paris, France
[4] Royal Prince Alfred Hosp, Dept Melanoma & Surg Oncol, Sydney, NSW, Australia
[5] Univ Sydney, Fac Med & Hlth, Sydney, NSW, Australia
[6] Melanoma Inst Australia, Sydney, NSW, Australia
[7] East & North NHS Trust, Mt Vernon Canc Ctr, Northwood, Middx, England
[8] Odense Univ Hosp, Dept Oncol, Odense, Denmark
[9] Nantes Univ, CNRS, UMR 1302, INSERM,INCIT,EMR6001,Immunol & New Concepts Immuno, Nantes, France
[10] Univ Hosp, Skin Canc Ctr, Zurich, Switzerland
[11] Univ LAquila, Dermatol Dept Biotechnol & Appl Clin Sci, Laquila, Italy
[12] Carol Davila Univ Med & Pharm Bucharest, Elias Univ Hosp Bucharest, Dept Oncol Dermatol, Bucharest, Romania
[13] Queen Mary Univ London, Barts & London Sch Med & Dent, Ctr Cell Biol & Cutaneous Res, Blizard Inst, London, England
[14] Univ Hosp UKSH, Dept Dermatol, Campus Kiel, Kiel, Germany
[15] Med Univ Vienna, Dept Dermatol, Vienna, Austria
[16] Mil Med Acad, Med Fac, Dept Dermatol, Belgrade, Serbia
[17] Frankfurt Univ Hosp, Dept Dermatol Venereol & Allergol, Frankfurt, Germany
[18] Maastricht Univ, GROW Sch Oncol & Reprod, GROW, Maastricht, Netherlands
[19] Maastricht Univ, Med Ctr, Dept Dermatol, Maastricht, Netherlands
[20] Aristotle Univ Thessaloniki, Dept Dermatol 1, Thessaloniki, Greece
[21] Univ Barcelona, Hosp Clin Barcelona, CIBER Enfermedades Raras, IDIBAPS,Dermatol Dept,Inst Carlos III, Villarroel 170, E-08036 Barcelona, Spain
[22] Univ Libre Bruxelles, Univ Hosp Erasme, Dept Dermatol, Brussels, Belgium
[23] Hosp Univ Virgen Macarena, Dept Med & Surg Dermatol Serv, E-41009 Seville, Spain
[24] Univ Roma La Sapienza, Dermatol Unit, Rome, Italy
[25] Fdn Policlin Univ A Gemelli IRCCS, Dipartimento Sci Med & Chirurg Addominali Endocrin, UOC Dermatol, IRCCS, Rome, Italy
[26] Univ Cattolica Sacro Cuore, Dermatol, Rome, Italy
[27] Univ Paris Saclay, Ambroise Pare Hosp, AP HP, Dept Gen & Oncol Dermatol, Boulogne Billancourt, France
[28] Univ Paris Saclay, UVSQ, EA Biomarkers Cancerol & Hematooncol 4340, Boulogne Billancourt, France
[29] Fdn Policlin Univ A Gemelli IRCCS, Dipartimento Diagnost Immagini Radioterapia Oncol, UOC Radioterapia Oncol, UOC Radioterapia Oncolog, Rome, Italy
[30] Aristotle Univ Thessaloniki, Papageorgiou Hosp, Dept Dermatol, Dept Med, Thessaloniki, Greece
[31] Coimbra Hosp & Univ Ctr, Dept Dermatol, Coimbra, Portugal
[32] Univ Trieste, Dept Dermatol, Trieste, Italy
[33] Charles Univ Prague, Fac Med 3, Dept Dermatovenereol, Prague, Czech Republic
[34] Univ Med Ctr Utrecht, Princess Maxima Ctr, Utrecht, Netherlands
[35] Princess Maxima Ctr, Utrecht, Netherlands
[36] Tech Univ Munich, Comprehens Canc Ctr Munich, Munich, Germany
[37] Ludwig Maximilian Univ Munich, Munich, Germany
[38] Aix Marseille Univ, CERIMED, Marseille, France
[39] Univ Manchester, Div Canc Sci, Manchester, Lancs, England
[40] Christie NHS Fdn Trust, Dept Med Oncol, Manchester, Lancs, England
关键词
Cutaneous squamous cell carcinoma; Locally advanced; Metastatic; Treatment; Surgical excision; Radiotherapy; Adjuvant; Anti-PD-1; antibody; Cemiplimab; Follow-up; SOLID-ORGAN TRANSPLANT; MOHS MICROGRAPHIC SURGERY; NONMELANOMA SKIN-CANCER; IMMUNE CHECKPOINT INHIBITORS; GROWTH-FACTOR RECEPTOR; IN-TRANSIT METASTASIS; CERVICAL LYMPH-NODES; PHASE-II; HIGH-RISK; ADJUVANT RADIOTHERAPY;
D O I
10.1016/j.ejca.2023.113252
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
In order to update recommendations on treatment, supportive care, education, and follow-up of patients with invasive cutaneous squamous cell carcinoma (cSCC), a multidisciplinary panel of experts from the European Association of Dermato-Oncology (EADO), the European Dermatology Forum (EDF), the European Society for Radiotherapy and Oncology (ESTRO), the European Union of Medical Specialists (UEMS), the European Academy of Dermatology and Venereology (EADV), and the European Organisation of Research and Treatment of Cancer (EORTC) was formed. Recommendations were based on an evidence-based literature review, guidelines, and expert consensus. Treatment recommendations are presented for common primary cSCC (low risk, high risk), locally advanced cSCC, regional metastatic cSCC (operable or inoperable), and distant metastatic cSCC. For common primary cSCC, the first-line treatment is surgical excision with postoperative margin assessment or micrographically controlled surgery. Achieving clear surgical margins is the most important treatment consideration for patients with cSCCs amenable to surgery. Regarding adjuvant radiotherapy for patients with high-risk localised cSCC with clear surgical margins, current evidence has not shown significant benefit for those with at least one high-risk factor. Radiotherapy should be considered as the primary treatment for non-surgical candidates/tumours. For cSCC with cytologically or histologically confirmed regional nodal metastasis, lymph node dissection is recommended. For patients with metastatic or locally advanced cSCC who are not candidates for curative surgery or radiotherapy, anti-PD-1 agents are the first-line systemic treatment, with cemiplimab being the first approved systemic agent for advanced cSCC by the Food and Drugs Administration/ European Medicines Agency. Second-line systemic treatments for advanced cSCC, include epidermal growth factor receptor inhibitors (cetuximab) combined with chemotherapy or radiotherapy. Multidisciplinary board decisions are mandatory for all patients with advanced cSCC, considering the risks of toxicity, the age and frailty of patients, and co-morbidities, including immunosuppression. Patients should be engaged in informed, shared decision-making on management and be provided with the best supportive care to improve symptom management and quality of life. The frequency of follow-up visits and investigations for subsequent new cSCC depends on underlying risk characteristics. (c) 2023 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
引用
收藏
页数:31
相关论文
共 230 条
  • [1] Checkpoint inhibitor therapy for cancer in solid organ transplantation recipients: an institutional experience and a systematic review of the literature
    Abdel-Wahab, Noha
    Safa, Houssein
    Abudayyeh, Ala
    Johnson, Daniel H.
    Van Anh Trinh
    Zobniw, Chrystia M.
    Lin, Heather
    Wong, Michael K.
    Abdelrahim, Maen
    Gaber, A. Osama
    Suarez-Almazor, Maria E.
    Diab, Adi
    [J]. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
  • [2] Immune Checkpoint Inhibitors and the Risk of Allograft Rejection: A Comprehensive Analysis on an Emerging Issue
    Aguirre, Luis E.
    Guzman, Maria E.
    Lopes, Gilberto
    Hurley, Judith
    [J]. ONCOLOGIST, 2019, 24 (03) : 394 - 401
  • [3] Risk of Invasive Cutaneous Squamous Cell Carcinoma After Different Treatments for Actinic Keratosis A Secondary Analysis of a Randomized Clinical Trial
    Ahmady, Shima
    Jansen, Maud H. E.
    Nelemans, Patty J.
    Kessels, Janneke P. H. M.
    Arits, Aimee H. M. M.
    de Rooij, Michette J. M.
    Essers, Brigitte A. B.
    Quaedvlieg, Patricia J. F.
    Kelleners-Smeets, Nicole W. J.
    Mosterd, Klara
    [J]. JAMA DERMATOLOGY, 2022, 158 (06) : 634 - 640
  • [4] Guidelines of care for the management of cutaneous squamous cell carcinoma
    Alam, Murad
    Armstrong, April
    Baum, Christian
    Bordeaux, Jeremy S.
    Brown, Marc
    Busam, Klaus J.
    Eisen, Daniel B.
    Iyengar, Vivek
    Lober, Clifford
    Margolis, David J.
    Messina, Jane
    Miller, Alexander
    Miller, Stanley
    Mostow, Eliot
    Mowad, Christen
    Nehal, Kishwer
    Schmitt-Burr, Kristi
    Sekulic, Aleksandar
    Storrs, Paul
    Teng, Joyce
    Yu, Siegrid
    Huang, Conway
    Boyer, Kevin
    Begolka, Wendy Smith
    Bichakjian, Christopher
    Kim, John Y. S.
    Kozlow, Jeffrey H.
    Mittal, Bharat
    Moyer, Jeffrey
    Olenecki, Thomas
    Rodgers, Phillip
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2018, 78 (03) : 560 - 578
  • [5] Successful Administration of Cemiplimab to a Patient With Advanced Cutaneous Squamous Cell Carcinoma After Renal Transplantation
    Ali, Saad Ahmad
    Arman, Huseyin Emre
    Patel, Anuj Amrut
    Birhiray, Ruemu Ejedafeta
    [J]. JCO ONCOLOGY PRACTICE, 2020, 16 (03) : 137 - +
  • [6] Intralesional methotrexate treatment for keratoacanthoma tumors: A retrospective study and review of the literature
    Annest, Nicole M.
    VanBeek, Marta J.
    Arpey, Christopher J.
    Whitaker, Duane C.
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2007, 56 (06) : 989 - 993
  • [7] [Anonymous], 2020, PALL CAR
  • [8] Japanese Dermatological Association Guidelines: Outlines of Guidelines for Cutaneous Squamous Cell Carcinoma 2020
    Ansai, Shin-ichi
    Umebayashi, Yoshihiro
    Katsumata, Noriyuki
    Kato, Hiroshi
    Kadono, Takafumi
    Takai, Toshihiro
    Namiki, Takeshi
    Nakagawa, Masahiro
    Soejima, Toshinori
    Koga, Hiroshi
    Sugaya, Makoto
    [J]. JOURNAL OF DERMATOLOGY, 2021, 48 (07) : E288 - E311
  • [9] Cutaneous metastatic squamous cell carcinoma to the parotid gland: Analysis and outcome
    Audet, N
    Palme, CE
    Gullane, PJ
    Gilbert, RW
    Brown, DH
    Irish, J
    Neligan, P
    [J]. HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 2004, 26 (08): : 727 - 732
  • [10] Narrower clinical margin in high or very high-risk squamous cell carcinoma: a retrospective, multicenter study of 1,000 patients
    Baba, Natsuki
    Kato, Hiroshi
    Nakamura, Motoki
    Matsushita, Shigeto
    Aoki, Megumi
    Fujimoto, Noriki
    Kato, Takeshi
    Iino, Shiro
    Saito, Shintaro
    Yasuda, Masahito
    Asai, Jun
    Ishikawa, Masashi
    Yatsushiro, Hiroshi
    Kawahara, Yu
    Matsuya, Taisuke
    Araki, Ryuichiro
    Teramoto, Yukiko
    Hasegawa, Minoru
    Tokunaga, Takahiro
    Nakamura, Yasuhiro
    [J]. JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2022, 20 (08): : 1088 - 1099